The drug is licensed to Ranbaxy Laboratories from Cipher Pharmaceuticals Inc of Mississauga, Ontario.
It is currently protected by two issued patents listed in the Food and Drug Administration's approved drug products list, which expire in September 2021, the company said in a statement.
"Ranbaxy Laboratories Inc, the wholly-owned subsidiary of the company has received a Paragraph IV certification notice of filing from Watson Laboratories Inc of an abbreviated new drug application to the US Food and Drug Administration for a generic version of Absorica," it said.
As per the regulatory norms in the US, a generic firm can file an abbreviated new drug application challenging patent of drug under Paragraph IV certification, which if successful, gives the challenger 180
Suspected human hair in tablet cited in Ranbaxy ban
Why Ranbaxy's big setback is not yet OVER
CLT20: Rajasthan face uphill task against Mumbai in opener
US FDA tightens regulatory noose on Indian drug firms
USFDA issues import alert on Ranbaxy's Mohali plant